AbbVie: Rinvoq achieved superiority v. Dupixent in atopic dermatitis study

 

• AbbVie (ABBV -1.0%) has reported top-line data from Phase 3b Heads Up study, evaluating its Rinvoq (upadacitinib) versus Sanofi / Regeneron's Dupixent (dupilumab), in adults with atopic dermatitis.
• Safety profile of upadacitinib was consistent with previous atopic dermatitis studies, with no new safety risks observed
• 71% of the patients in upadacitinib arm achieved 75% improvement in eczema severity index at week 16 (primary endpoint), compared to 61% of dupilumab-treated patients.
• Additionally, upadacitinib also showed superiority compared to dupilumab for all ranked secondary endpoints, including in early improvements of itch and skin clearance.
• Full results from the study will be submitted for publication in a peer-reviewed journal.
• Yesterday, the company announced that upadacitinib topped placebo at helping previously untreated ulcerative colitis patients achieve remission by the eight-week mark. 26% of the patients in Rinvoq arm hit that benchmark, versus just 5% on placebo.
• https://seekingalpha.com/news/3643327-abbvie-says-rinvoq-achieved-superiority-versus-dupixent-in-atopic-dermatitis-study